Miniatura

Fitxers

Incidence and Clinical Significance of Recompensation After HCV Cure.pdf (1.35 MB)

Tipus de document

Article

Data de publicació

2025-11-24

Tots els drets reservats

Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/227627

Incidence and Clinical Significance of Recompensation After HCV Cure

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1016/j.cgh.2025.04.026

Resum

BACKGROUND & AIMS: Baveno VII has proposed criteria for cirrhosis recompensation, but their prognostic significance in decompensated patients cured of hepatitis C virus (HCV) deserves further investigation. Thus, we studied the incidence and impact of recompensation after HCV cure as well as its predictors. METHODS: A total of 2570 patients with advanced chronic liver disease (ACLD) from 10 European centers were retrospectively included, including 2209 and 361 patients with compensated ACLD and decompensated cirrhosis who achieved sustained virologic response to direct-acting antivirals (DAAs). The association between achieving recompensation and clinical outcomes (hepatocellular carcinoma [HCC], portal vein thrombosis [PVT], and [liver-related] death) was investigated. RESULTS: During a median follow-up of 8.4 years from treatment initiation, 132 patients (36.6%) achieved recompensation. Lower albumin levels and diabetes were negatively associated with achieving recompensation. The incidence rates of liver-related death (4.2 vs 8.8 per 100 patient-years) and PVT (2.7 vs 5.4) were substantially lower after recompensation vs in the nonrecompensated state, while HCC incidence remained high (3.9 vs 5.5). Compared with decompensated cirrhosis, achieving recompensation was independently associated with decreased risks of subsequent liver-related death (adjusted hazard ratio, 0.384; 95% confi-dence interval, 0.225-0.655) and of PVT (adjusted hazard ratio, 0.421; 95% confidence interval, 0.224-0.759), but both risks remained higher than in compensated ACLD. Importantly, HCC incidence was not reduced as compared with decompensated cirrhosis. CONCLUSIONS: Recompensation after HCV cure is associated with substantially decreased risks of (liver-related) mortality and PVT, but not of HCC.

Matèries

Matèries (anglès)

Citació

Col·leccions

Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer)

Citació

SEMMLER, Georg, LENS GARCÍA, Sabela, HIDALGO, Álvaro, LOPEZ, Sonia alonso, PEREZ-PEREZ, Maria, DAJTI, Elton, KABELITZ, Martin, ZANAGA, Paola, HOFER, Benedikt silvester, MARIÑO MENDEZ, Zoe, MANZANO, Marisa luisa, PAYERAS, Isabel, PONS, Monica, BRUNI, Angelo, ZANETTO, Alberto, BURGHART, Lukas, ECKER, Dominik, SIMONIS, Lucie, POCURULL APARICIO, Anna, FRITZ, Laurenz, COLLAZOS CLEMENTE, Cristina, NEUMAYER, Daniela, BALCAR, Lorenz, JACHS, Mathias, REIBERGER, Thomas, RUSSO, Francesco paolo, MAASOUMY, Benjamin, GENESCA, Joan, BANARES, Rafael, FORNS BERNHARDT, Xavier, FERNANDEZ, Inmaculada, MANDORFER, Mattias. Incidence and Clinical Significance of Recompensation After HCV Cure. _Clinical Gastroenterology And Hepatology_. 2025. Vol.  23, núm. 13, pàgs. 2488-2498. [consulta: 28 de febrer de 2026]. ISSN: Semmler, Georg; Lens, Sabela; Hidalgo, Alvaro; Lopez, Sonia Alonso; Perez-Perez, Maria; Dajti, Elton; Kabelitz, Martin; Zanaga, Paola; Hofer, Benedikt (2025). Incidence and Clinical Significance of Recompensation After HCV Cure. Clinical Gastroenterology And Hepatology, 23(13), 2488-2498. DOI: 10.1016/j.cgh.2025.04.026. [Disponible a: https://hdl.handle.net/2445/227627]

Exportar metadades

JSON - METS

Compartir registre